Skip to main content

Ovarian Cancer - Diagnosing a Silent Killer

Objective

In Europe 63000 ovarian cancer cases are diagnosed and 41000 ovarian cancer patients die annually. 75% of patients are diagnosed at advanced stages due to an asymptomatic course. 75% of these patients die within 5 years. Treatment involves surgery follow ed by chemotherapy. However, 25% of patients relapse within 6 months after initial treatment. There is doubt whether these patients benefit from this therapy at all. Recurrent disease is diagnosed by clinical evidences or by CA125 dynamics. But detection is limited due to lack of sensitivity and specificity, as is the case with primary diagnosis. Currently, there is no method to detect minimal disease, the first indicator of therapy failure and precursor of recurrence, which inevitably leaves specific t races through out the body. There is strong need for molecular-oriented research to detect minimal disease in order to disburden patients from an inefficient and toxic therapy. The aim of this project is to define clinically useful molecular-orientated ea rly detection of minimal disease in ovarian cancer that can identify patients not responding to the standard therapy at the time of surgery. This will eventually lead to alternative therapy modalities, which can really bring benefits to this group of pat ients. "Signatures" that signal the presence of minimal disease will be systematically investigated at various molecular levels (DNA, RNA and protein) and in a broad spectrum of biological materials (tumour tissue, disseminated tumour cells, sera, white blood cells, ascites) from ovarian cancer patients. Profiling of chromosomal loss or gain, gene methylation and mutations, mRNA expression and protein will be analyzed. Specific signatures that predict patients¿ outcome or indicate minimal disease, even tually suitable for early primary diagnosis, will be extracted.

Field of science

  • /natural sciences/computer and information sciences/data science/data analysis
  • /natural sciences/biological sciences/genetics and heredity/rna
  • /natural sciences/biological sciences/biochemistry/biomolecules/proteins
  • /medical and health sciences/clinical medicine/surgery
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/drug resistance
  • /natural sciences/biological sciences/genetics and heredity/mutation
  • /medical and health sciences/clinical medicine/cancer

Call for proposal

FP6-2004-LIFESCIHEALTH-5
See other projects for this call

Funding Scheme

STREP - Specific Targeted Research Project

Coordinator

MEDIZINISCHE UNIVERSITÄT WIEN
Address
Spitalgasse 23
Vienna
Austria

Participants (13)

BIOFOCUS GESELLSCHAFT FÜR BIOLOGISCHE ANALYTIK MBH
Germany
Address
Berghäuser Str. 295
Recklinghausen
CENTRE RÉGIONAL DE LUTTE CONTRE LE CANCER DE MONTPELLIER
France
Address
Rue De La Croix Verte
Montpellier
CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN
Germany
Address
Schumannstraße 20/21
Berlin
DEUTSCHES KREBSFORSCHUNGSZENTRUM
Germany
Address
Im Neuenheimer Feld 280
Heidelberg
EMERGENTEC BIODEVELOPMENT GMBH
Austria
Address
Rathausstrasse 5/3
Vienna
ERASMUS MEDISCH CENTRUM ROTTERDAM
Netherlands
Address
Dr. Molewaterplein 50
Rotterdam
INSTITUT PAOLI-CALMETTES
France
Address
232 Bd Ste Marguerite
Marseille
KAPLAN MEDICAL CENTER
Israel
Address
Po Box 1
Rehovot
KATHOLIEKE UNIVERSITEIT LEUVEN
Belgium
Address
Oude Markt 13
Leuven
UNIVERSITÄT FÜR WEITERBILDUNG KREMS
Austria
Address
Dr. Karl Dorrekstrasse 30
Krems
UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF
Germany
Address
Martinistr. 52
Hamburg
VIENNALAB LABORDIAGNOSTIKA GMBH
Austria
Address
Am Kanal 27
Vienna
VITATEQ BIOTECHNOLOGY GMBH
Austria
Address
Innrain 66
Innsbruck